羧酸酯酶1基因多态性在药物反应性中的研究进展  

Research Progress of Carboxylesterase 1 Gene Polymorphism in Drug Responsiveness

作　　者：杨婉花[1] 刘亮明[2] YANG Wanhua;LIU Liangming(Department of Cadre Elderly,Shanghai Songjiang District Central Hospital,Shanghai 201600,China;Department of Infectious Disease,Shanghai Songjiang District Central Hospital,Shanghai 201600,China)

机构地区：[1]上海市松江区中心医院干部老年科,上海201600 [2]上海市松江区中心医院感染科,上海201600

出　　处：《医学综述》2023年第16期3134-3139,共6页Medical Recapitulate

基　　金：国家自然科学基金(81770612)。

摘　　要：哺乳动物羧酸酯酶(CES)是丝氨酸水解酶超家族的关键酶,其中CES1可直接影响多种内源性酯类、含酯类药物的代谢结果。经过CES1代谢的酯类药物的疗效存在显著个体差异,主要表现为同样的药物剂量在不同的患者应用中可能有效或无效,甚至出现不良反应,而药物反应性不同与CES基因多态性密切相关。因此,遗传学和代谢学的组合研究在患者的药物精准治疗中具有指导意义,而细化CES1基因分型在提高患者药物治疗的有效性、避免不良反应方面具有重要的预测意义。Mammalian carboxylesterase(CES)is a key enzyme in the serine hydrolase superfamily,among which,CES1 affects the metabolic results of a variety of endogenous esters and ester-containing drugs.There are great differences in the efficacy of various ester drugs metabolized by CES1,mainly manifested as the same drug dosage may be effective or ineffective,even adverse reactions in different patients,which is closely related to the polymorphism of the CES gene.Therefore,the combined research of genetics and metabolism has guiding significance for the precise treatment of the patients,and the refinement of CES1 genotype has important predictive significance in improving the drug effectiveness and avoiding adverse reactions of the treatment.

关 键 词：羧酸酯酶1 基因多态性 药物代谢 药物反应性 

分 类 号：R341[医药卫生—基础医学]